市場調査レポート

商品コード

1193254

B型慢性肝炎市場：薬物クラス別、性別、流通チャネル別：世界の機会分析および産業予測、2021-2031年

Chronic Hepatitis B Market By Drug Class, By Gender, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2021-2031

出版日: 2022年10月01日 | 発行: Allied Market Research

| ページ情報: 英文 290 Pages | 納期: 2～3営業日

価格

PDF (Single User License)

USD 5,730 898,234円

レポートPDFを1つのPCでご利用頂けるライセンスです。ライセンスを付与されたPCでのみレポートPDFの保存、表示、利用が可能です。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は1回だけ可能です。印刷したレポートの利用もPDFのライセンス保持者になります。回覧のための複製も原則NGです。

PDF (5-user License)

USD 6,450 1,011,102円

レポートPDFを5名でご利用頂けるライセンスです。ライセンスを付与されたPCでのみレポートPDFの保存、表示、利用が可能です。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は5回可能です。印刷したレポートの利用もPDFのライセンス保持者5名となります。

PDF (Enterprise User License) & Excel (Data Pack) & Free Update

USD 9,600 1,504,896円

レポートPDFとExcel定量データをひとつの企業、及びその子会社でご利用頂けるライセンスです。ライセンスを付与されたPCでのみレポートPDFとExcelの保存、表示、利用が可能です。PDFとExcel内のテキスト等のコピー＆ペーストは可能です。PDFとExcelの印刷回数の制限はありません。印刷したレポートの利用は企業、及びその子会社内にて共有可能です。無料でレポートのアップデートがご利用いただけます。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=156.76円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

B型慢性肝炎の世界市場は、2021年に45億8980万米ドル、2031年には62億1315万米ドルに達し、2022年から2031年にかけてCAGR3.0%で成長すると予測されています。

B型肝炎は、肝臓を攻撃するウイルス感染症で、急性疾患と慢性疾患の両方を引き起こす可能性があります。B型肝炎は、B型肝炎ウイルス（HBV）によって引き起こされる、生命を脅かす可能性のある肝臓感染症です。B型肝炎は慢性感染を引き起こし、肝硬変や肝臓がんによる死亡リスクを高めると言われています。

B型肝炎の罹患率の上昇とB型肝炎に関する認知度の向上が、市場の成長を後押ししています。例えば、2022年6月に発表された世界保健機関（WHO）の報告書によると、世界では2019年に推定2億9600万人がB型慢性肝炎に感染しており、毎年150万人が新たに感染しているとのことです。したがって、世界的にB型肝炎の有病率が増加することは、市場の成長を後押しします。

概要
- 市場規模および予測
男性
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別
- 男性B型慢性肝炎（CHB）市場：年齢層別
  - 成人市場規模・予測：地域別
  - ジェリアート市場規模推移・予測：地域別
女性
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別
- 女性B型慢性肝炎（CHB）市場：年齢層別
  - 成人市場規模・予測：地域別
  - ジェリアート市場規模・予測：地域別

第6章 B型慢性肝炎（CHB）市場：流通チャネル別

概要
- 市場規模・予測
病院薬局
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別
ドラッグストア、小売薬局
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別
オンラインプロバイダー
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別

第7章慢性肝炎B（CHB）市場：地域別

概要
- 市場規模・予測
北米
- 主要動向と機会
- 北米市場規模・予測：薬効分類別
- 北米市場規模・予測：男女別
  - 北米男性B型慢性肝炎（CHB）市場：年齢層別
  - 北米女性B型慢性肝炎（CHB）市場：年齢層別
- 北米の市場規模・予測：流通チャネル別
- 北米市場規模・予測：国別
  - 米国
  - カナダ
  - メキシコ
欧州
- 主要動向と機会
- 欧州の市場規模・予測：薬物クラス別
- 欧州市場規模・予測：男女別
  - 欧州男性B型慢性肝炎（CHB）市場：年齢層別
  - 欧州女性B型慢性肝炎（CHB）市場：年齢層別
- 欧州市場規模・予測：流通チャネル別
- 欧州市場規模・予測：国別
  - ドイツ
  - フランス
  - 英国
  - イタリア
  - スペイン
  - その他欧州
アジア太平洋地域
- 主な動向と機会
- アジア太平洋地域の市場規模・予測：薬物クラス別
- アジア太平洋地域の市場規模・予測：男女別
  - アジア太平洋地域の男性B型慢性肝炎（CHB）市場：年齢層別
  - アジア太平洋地域の女性B型慢性肝炎（CHB）市場：年齢層別
- アジア太平洋地域の市場規模・予測：流通チャネル別
- アジア太平洋地域の市場規模・予測：国別
  - 日本
  - 中国
  - オーストラリア
  - インド
  - 韓国
  - その他アジア太平洋地域
LAMEA
- 主な動向と機会
- LAMEAの市場規模・予測：薬物クラス別
- LAMEAの市場規模・予測：男女別
  - LAMEA男性B型慢性肝炎（CHB）市場：年齢層別
  - LAMEAの女性B型慢性肝炎（CHB）市場：年齢層別
- LAMEAの市場規模・予測：流通チャネル別
- LAMEAの市場規模・予測：国別
  - ブラジル
  - サウジアラビア
  - 南アフリカ共和国
  - LAMEAの残りの地域

第8章企業情勢

イントロダクション
主要成功戦略
主要10社の製品マッピング
競合ダッシュボード
競合のヒートマップ
主な発展

第9章企業プロファイル

GlaxoSmithKline（GSK）
Gilead Sciences, Inc.
Merck & Co. Inc.
Bristol Myers Squibb Co.
Teva Pharmaceutical Industries Limited
zydus cadila
Novartis AG
F. Hoffman La Roche, Ltd.
Viatris Inc.（Mylan NV）
Cipla Ltd

図表

LIST OF TABLES

TABLE 1. GLOBAL CHRONIC HEPATITIS B (CHB) MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 2. CHRONIC HEPATITIS B (CHB) MARKET, FOR ANTIVIRALS, BY REGION, 2021-2031 ($MILLION)
TABLE 3. CHRONIC HEPATITIS B (CHB) MARKET FOR ANTIVIRALS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 4. CHRONIC HEPATITIS B (CHB) MARKET, FOR IMMUNE MODULATORS, BY REGION, 2021-2031 ($MILLION)
TABLE 5. CHRONIC HEPATITIS B (CHB) MARKET FOR IMMUNE MODULATORS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 6. GLOBAL CHRONIC HEPATITIS B (CHB) MARKET, BY GENDER, 2021-2031 ($MILLION)
TABLE 7. CHRONIC HEPATITIS B (CHB) MARKET, FOR MALE, BY REGION, 2021-2031 ($MILLION)
TABLE 8. CHRONIC HEPATITIS B (CHB) MARKET FOR MALE, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 9. GLOBAL MALE CHRONIC HEPATITIS B (CHB) MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 10. CHRONIC HEPATITIS B (CHB) MARKET, FOR ADULT, BY REGION, 2021-2031 ($MILLION)
TABLE 11. CHRONIC HEPATITIS B (CHB) MARKET, FOR GERIARTIC, BY REGION, 2021-2031 ($MILLION)
TABLE 12. CHRONIC HEPATITIS B (CHB) MARKET, FOR FEMALE, BY REGION, 2021-2031 ($MILLION)
TABLE 13. CHRONIC HEPATITIS B (CHB) MARKET FOR FEMALE, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 14. GLOBAL FEMALE CHRONIC HEPATITIS B (CHB) MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 15. CHRONIC HEPATITIS B (CHB) MARKET, FOR ADULT, BY REGION, 2021-2031 ($MILLION)
TABLE 16. CHRONIC HEPATITIS B (CHB) MARKET, FOR GERIARTIC, BY REGION, 2021-2031 ($MILLION)
TABLE 17. GLOBAL CHRONIC HEPATITIS B (CHB) MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 18. CHRONIC HEPATITIS B (CHB) MARKET, FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
TABLE 19. CHRONIC HEPATITIS B (CHB) MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 20. CHRONIC HEPATITIS B (CHB) MARKET, FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
TABLE 21. CHRONIC HEPATITIS B (CHB) MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 22. CHRONIC HEPATITIS B (CHB) MARKET, FOR ONLINE PROVIDERS, BY REGION, 2021-2031 ($MILLION)
TABLE 23. CHRONIC HEPATITIS B (CHB) MARKET FOR ONLINE PROVIDERS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 24. CHRONIC HEPATITIS B (CHB) MARKET, BY REGION, 2021-2031 ($MILLION)
TABLE 25. NORTH AMERICA CHRONIC HEPATITIS B (CHB) MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 26. NORTH AMERICA CHRONIC HEPATITIS B (CHB) MARKET, BY GENDER, 2021-2031 ($MILLION)
TABLE 27. NORTH AMERICA MALE CHRONIC HEPATITIS B (CHB) MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 28. NORTH AMERICA FEMALE CHRONIC HEPATITIS B (CHB) MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 29. NORTH AMERICA CHRONIC HEPATITIS B (CHB) MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 30. NORTH AMERICA CHRONIC HEPATITIS B (CHB) MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 31. U.S. CHRONIC HEPATITIS B (CHB) MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 32. U.S. CHRONIC HEPATITIS B (CHB) MARKET, BY GENDER, 2021-2031 ($MILLION)
TABLE 33. U.S. CHRONIC HEPATITIS B (CHB) MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 34. CANADA CHRONIC HEPATITIS B (CHB) MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 35. CANADA CHRONIC HEPATITIS B (CHB) MARKET, BY GENDER, 2021-2031 ($MILLION)
TABLE 36. CANADA CHRONIC HEPATITIS B (CHB) MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 37. MEXICO CHRONIC HEPATITIS B (CHB) MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 38. MEXICO CHRONIC HEPATITIS B (CHB) MARKET, BY GENDER, 2021-2031 ($MILLION)
TABLE 39. MEXICO CHRONIC HEPATITIS B (CHB) MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 40. EUROPE CHRONIC HEPATITIS B (CHB) MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 41. EUROPE CHRONIC HEPATITIS B (CHB) MARKET, BY GENDER, 2021-2031 ($MILLION)
TABLE 42. EUROPE MALE CHRONIC HEPATITIS B (CHB) MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 43. EUROPE FEMALE CHRONIC HEPATITIS B (CHB) MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 44. EUROPE CHRONIC HEPATITIS B (CHB) MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 45. EUROPE CHRONIC HEPATITIS B (CHB) MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 46. GERMANY CHRONIC HEPATITIS B (CHB) MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 47. GERMANY CHRONIC HEPATITIS B (CHB) MARKET, BY GENDER, 2021-2031 ($MILLION)
TABLE 48. GERMANY CHRONIC HEPATITIS B (CHB) MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 49. FRANCE CHRONIC HEPATITIS B (CHB) MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 50. FRANCE CHRONIC HEPATITIS B (CHB) MARKET, BY GENDER, 2021-2031 ($MILLION)
TABLE 51. FRANCE CHRONIC HEPATITIS B (CHB) MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 52. UK CHRONIC HEPATITIS B (CHB) MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 53. UK CHRONIC HEPATITIS B (CHB) MARKET, BY GENDER, 2021-2031 ($MILLION)
TABLE 54. UK CHRONIC HEPATITIS B (CHB) MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 55. ITALY CHRONIC HEPATITIS B (CHB) MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 56. ITALY CHRONIC HEPATITIS B (CHB) MARKET, BY GENDER, 2021-2031 ($MILLION)
TABLE 57. ITALY CHRONIC HEPATITIS B (CHB) MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 58. SPAIN CHRONIC HEPATITIS B (CHB) MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 59. SPAIN CHRONIC HEPATITIS B (CHB) MARKET, BY GENDER, 2021-2031 ($MILLION)
TABLE 60. SPAIN CHRONIC HEPATITIS B (CHB) MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 61. REST OF EUROPE CHRONIC HEPATITIS B (CHB) MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 62. REST OF EUROPE CHRONIC HEPATITIS B (CHB) MARKET, BY GENDER, 2021-2031 ($MILLION)
TABLE 63. REST OF EUROPE CHRONIC HEPATITIS B (CHB) MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 64. ASIA-PACIFIC CHRONIC HEPATITIS B (CHB) MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 65. ASIA-PACIFIC CHRONIC HEPATITIS B (CHB) MARKET, BY GENDER, 2021-2031 ($MILLION)
TABLE 66. ASIA-PACIFIC MALE CHRONIC HEPATITIS B (CHB) MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 67. ASIA-PACIFIC FEMALE CHRONIC HEPATITIS B (CHB) MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 68. ASIA-PACIFIC CHRONIC HEPATITIS B (CHB) MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 69. ASIA-PACIFIC CHRONIC HEPATITIS B (CHB) MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 70. JAPAN CHRONIC HEPATITIS B (CHB) MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 71. JAPAN CHRONIC HEPATITIS B (CHB) MARKET, BY GENDER, 2021-2031 ($MILLION)
TABLE 72. JAPAN CHRONIC HEPATITIS B (CHB) MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 73. CHINA CHRONIC HEPATITIS B (CHB) MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 74. CHINA CHRONIC HEPATITIS B (CHB) MARKET, BY GENDER, 2021-2031 ($MILLION)
TABLE 75. CHINA CHRONIC HEPATITIS B (CHB) MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 76. AUSTRALIA CHRONIC HEPATITIS B (CHB) MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 77. AUSTRALIA CHRONIC HEPATITIS B (CHB) MARKET, BY GENDER, 2021-2031 ($MILLION)
TABLE 78. AUSTRALIA CHRONIC HEPATITIS B (CHB) MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 79. INDIA CHRONIC HEPATITIS B (CHB) MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 80. INDIA CHRONIC HEPATITIS B (CHB) MARKET, BY GENDER, 2021-2031 ($MILLION)
TABLE 81. INDIA CHRONIC HEPATITIS B (CHB) MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 82. SOUTH KOREA CHRONIC HEPATITIS B (CHB) MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 83. SOUTH KOREA CHRONIC HEPATITIS B (CHB) MARKET, BY GENDER, 2021-2031 ($MILLION)
TABLE 84. SOUTH KOREA CHRONIC HEPATITIS B (CHB) MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 85. REST OF ASIA-PACIFIC CHRONIC HEPATITIS B (CHB) MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 86. REST OF ASIA-PACIFIC CHRONIC HEPATITIS B (CHB) MARKET, BY GENDER, 2021-2031 ($MILLION)
TABLE 87. REST OF ASIA-PACIFIC CHRONIC HEPATITIS B (CHB) MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 88. LAMEA CHRONIC HEPATITIS B (CHB) MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 89. LAMEA CHRONIC HEPATITIS B (CHB) MARKET, BY GENDER, 2021-2031 ($MILLION)
TABLE 90. LAMEA MALE CHRONIC HEPATITIS B (CHB) MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 91. LAMEA FEMALE CHRONIC HEPATITIS B (CHB) MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 92. LAMEA CHRONIC HEPATITIS B (CHB) MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 93. LAMEA CHRONIC HEPATITIS B (CHB) MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 94. BRAZIL CHRONIC HEPATITIS B (CHB) MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 95. BRAZIL CHRONIC HEPATITIS B (CHB) MARKET, BY GENDER, 2021-2031 ($MILLION)
TABLE 96. BRAZIL CHRONIC HEPATITIS B (CHB) MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 97. SAUDI ARABIA CHRONIC HEPATITIS B (CHB) MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 98. SAUDI ARABIA CHRONIC HEPATITIS B (CHB) MARKET, BY GENDER, 2021-2031 ($MILLION)
TABLE 99. SAUDI ARABIA CHRONIC HEPATITIS B (CHB) MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 100. SOUTH AFRICA CHRONIC HEPATITIS B (CHB) MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 101. SOUTH AFRICA CHRONIC HEPATITIS B (CHB) MARKET, BY GENDER, 2021-2031 ($MILLION)
TABLE 102. SOUTH AFRICA CHRONIC HEPATITIS B (CHB) MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 103. REST OF LAMEA CHRONIC HEPATITIS B (CHB) MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 104. REST OF LAMEA CHRONIC HEPATITIS B (CHB) MARKET, BY GENDER, 2021-2031 ($MILLION)
TABLE 105. REST OF LAMEA CHRONIC HEPATITIS B (CHB) MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 106.GLAXOSMITHKLINE (GSK): COMPANY SNAPSHOT
TABLE 107.GLAXOSMITHKLINE (GSK): OPERATING SEGMENTS
TABLE 108.GLAXOSMITHKLINE (GSK): PRODUCT PORTFOLIO
TABLE 109.GLAXOSMITHKLINE (GSK): NET SALES,
TABLE 110.GLAXOSMITHKLINE (GSK): KEY STRATERGIES
TABLE 111.GILEAD SCIENCES, INC.: COMPANY SNAPSHOT
TABLE 112.GILEAD SCIENCES, INC.: OPERATING SEGMENTS
TABLE 113.GILEAD SCIENCES, INC.: PRODUCT PORTFOLIO
TABLE 114.GILEAD SCIENCES, INC.: NET SALES,
TABLE 115.GILEAD SCIENCES, INC.: KEY STRATERGIES
TABLE 116.MERCK & CO. INC.: COMPANY SNAPSHOT
TABLE 117.MERCK & CO. INC.: OPERATING SEGMENTS
TABLE 118.MERCK & CO. INC.: PRODUCT PORTFOLIO
TABLE 119.MERCK & CO. INC.: NET SALES,
TABLE 120.MERCK & CO. INC.: KEY STRATERGIES
TABLE 121.BRISTOL MYERS SQUIBB CO.: COMPANY SNAPSHOT
TABLE 122.BRISTOL MYERS SQUIBB CO.: OPERATING SEGMENTS
TABLE 123.BRISTOL MYERS SQUIBB CO.: PRODUCT PORTFOLIO
TABLE 124.BRISTOL MYERS SQUIBB CO.: NET SALES,
TABLE 125.BRISTOL MYERS SQUIBB CO.: KEY STRATERGIES
TABLE 126.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT
TABLE 127.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: OPERATING SEGMENTS
TABLE 128.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO
TABLE 129.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: NET SALES,
TABLE 130.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: KEY STRATERGIES
TABLE 131.ZYDUS CADILA: COMPANY SNAPSHOT
TABLE 132.ZYDUS CADILA: OPERATING SEGMENTS
TABLE 133.ZYDUS CADILA: PRODUCT PORTFOLIO
TABLE 134.ZYDUS CADILA: NET SALES,
TABLE 135.ZYDUS CADILA: KEY STRATERGIES
TABLE 136.NOVARTIS AG: COMPANY SNAPSHOT
TABLE 137.NOVARTIS AG: OPERATING SEGMENTS
TABLE 138.NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 139.NOVARTIS AG: NET SALES,
TABLE 140.NOVARTIS AG: KEY STRATERGIES
TABLE 141.F. HOFFMAN LA ROCHE, LTD.: COMPANY SNAPSHOT
TABLE 142.F. HOFFMAN LA ROCHE, LTD.: OPERATING SEGMENTS
TABLE 143.F. HOFFMAN LA ROCHE, LTD.: PRODUCT PORTFOLIO
TABLE 144.F. HOFFMAN LA ROCHE, LTD.: NET SALES,
TABLE 145.F. HOFFMAN LA ROCHE, LTD.: KEY STRATERGIES
TABLE 146.VIATRIS INC. (MYLAN NV): COMPANY SNAPSHOT
TABLE 147.VIATRIS INC. (MYLAN NV): OPERATING SEGMENTS
TABLE 148.VIATRIS INC. (MYLAN NV): PRODUCT PORTFOLIO
TABLE 149.VIATRIS INC. (MYLAN NV): NET SALES,
TABLE 150.VIATRIS INC. (MYLAN NV): KEY STRATERGIES
TABLE 151.CIPLA LTD: COMPANY SNAPSHOT
TABLE 152.CIPLA LTD: OPERATING SEGMENTS
TABLE 153.CIPLA LTD: PRODUCT PORTFOLIO
TABLE 154.CIPLA LTD: NET SALES,
TABLE 155.CIPLA LTD: KEY STRATERGIES

LIST OF FIGURES

FIGURE 1.CHRONIC HEPATITIS B (CHB) MARKET SEGMENTATION
FIGURE 2.CHRONIC HEPATITIS B (CHB) MARKET,2021-2031
FIGURE 3.CHRONIC HEPATITIS B (CHB) MARKET,2021-2031
FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
FIGURE 5.PORTER FIVE-1
FIGURE 6.PORTER FIVE-2
FIGURE 7.PORTER FIVE-3
FIGURE 8.PORTER FIVE-4
FIGURE 9.PORTER FIVE-5
FIGURE 10.TOP PLAYER POSITIONING
FIGURE 11.CHRONIC HEPATITIS B (CHB) MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 12.CHRONIC HEPATITIS B (CHB) MARKET,BY DRUG CLASS,2021(%)
FIGURE 13.COMPARATIVE SHARE ANALYSIS OF ANTIVIRALS CHRONIC HEPATITIS B (CHB) MARKET,2021-2031(%)
FIGURE 14.COMPARATIVE SHARE ANALYSIS OF IMMUNE MODULATORS CHRONIC HEPATITIS B (CHB) MARKET,2021-2031(%)
FIGURE 15.CHRONIC HEPATITIS B (CHB) MARKET,BY GENDER,2021(%)
FIGURE 16.COMPARATIVE SHARE ANALYSIS OF MALE CHRONIC HEPATITIS B (CHB) MARKET,2021-2031(%)
FIGURE 17.COMPARATIVE SHARE ANALYSIS OF FEMALE CHRONIC HEPATITIS B (CHB) MARKET,2021-2031(%)
FIGURE 18.CHRONIC HEPATITIS B (CHB) MARKET,BY DISTRIBUTION CHANNEL,2021(%)
FIGURE 19.COMPARATIVE SHARE ANALYSIS OF HOSPITAL PHARMACIES CHRONIC HEPATITIS B (CHB) MARKET,2021-2031(%)
FIGURE 20.COMPARATIVE SHARE ANALYSIS OF DRUG STORES AND RETAIL PHARMACIES CHRONIC HEPATITIS B (CHB) MARKET,2021-2031(%)
FIGURE 21.COMPARATIVE SHARE ANALYSIS OF ONLINE PROVIDERS CHRONIC HEPATITIS B (CHB) MARKET,2021-2031(%)
FIGURE 22.CHRONIC HEPATITIS B (CHB) MARKET BY REGION,2021
FIGURE 23.U.S. CHRONIC HEPATITIS B (CHB) MARKET,2021-2031($MILLION)
FIGURE 24.CANADA CHRONIC HEPATITIS B (CHB) MARKET,2021-2031($MILLION)
FIGURE 25.MEXICO CHRONIC HEPATITIS B (CHB) MARKET,2021-2031($MILLION)
FIGURE 26.GERMANY CHRONIC HEPATITIS B (CHB) MARKET,2021-2031($MILLION)
FIGURE 27.FRANCE CHRONIC HEPATITIS B (CHB) MARKET,2021-2031($MILLION)
FIGURE 28.UK CHRONIC HEPATITIS B (CHB) MARKET,2021-2031($MILLION)
FIGURE 29.ITALY CHRONIC HEPATITIS B (CHB) MARKET,2021-2031($MILLION)
FIGURE 30.SPAIN CHRONIC HEPATITIS B (CHB) MARKET,2021-2031($MILLION)
FIGURE 31.REST OF EUROPE CHRONIC HEPATITIS B (CHB) MARKET,2021-2031($MILLION)
FIGURE 32.JAPAN CHRONIC HEPATITIS B (CHB) MARKET,2021-2031($MILLION)
FIGURE 33.CHINA CHRONIC HEPATITIS B (CHB) MARKET,2021-2031($MILLION)
FIGURE 34.AUSTRALIA CHRONIC HEPATITIS B (CHB) MARKET,2021-2031($MILLION)
FIGURE 35.INDIA CHRONIC HEPATITIS B (CHB) MARKET,2021-2031($MILLION)
FIGURE 36.SOUTH KOREA CHRONIC HEPATITIS B (CHB) MARKET,2021-2031($MILLION)
FIGURE 37.REST OF ASIA-PACIFIC CHRONIC HEPATITIS B (CHB) MARKET,2021-2031($MILLION)
FIGURE 38.BRAZIL CHRONIC HEPATITIS B (CHB) MARKET,2021-2031($MILLION)
FIGURE 39.SAUDI ARABIA CHRONIC HEPATITIS B (CHB) MARKET,2021-2031($MILLION)
FIGURE 40.SOUTH AFRICA CHRONIC HEPATITIS B (CHB) MARKET,2021-2031($MILLION)
FIGURE 41.REST OF LAMEA CHRONIC HEPATITIS B (CHB) MARKET,2021-2031($MILLION)
FIGURE 42. TOP WINNING STRATEGIES, BY YEAR
FIGURE 43. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 44. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 45.PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 46.COMPETITIVE DASHBOARD
FIGURE 47.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
FIGURE 48.GLAXOSMITHKLINE (GSK).: NET SALES ,($MILLION)
FIGURE 49.GILEAD SCIENCES, INC..: NET SALES ,($MILLION)
FIGURE 50.MERCK & CO. INC..: NET SALES ,($MILLION)
FIGURE 51.BRISTOL MYERS SQUIBB CO..: NET SALES ,($MILLION)
FIGURE 52.TEVA PHARMACEUTICAL INDUSTRIES LIMITED.: NET SALES ,($MILLION)
FIGURE 53.ZYDUS CADILA.: NET SALES ,($MILLION)
FIGURE 54.NOVARTIS AG.: NET SALES ,($MILLION)
FIGURE 55.F. HOFFMAN LA ROCHE, LTD..: NET SALES ,($MILLION)
FIGURE 56.VIATRIS INC. (MYLAN NV).: NET SALES ,($MILLION)
FIGURE 57.CIPLA LTD.: NET SALES ,($MILLION)

Product Code: A31523

The global chronic hepatitis B market was valued at $4,589.8 million in 2021 and is projected to reach $6,213.15 million by 2031, registering a CAGR of 3.0% from 2022 to 2031. Hepatitis B is a viral infection that attacks the liver and can cause both acute and chronic disease. Hepatitis B is a potentially life-threatening liver infection caused by the hepatitis B virus (HBV). Hepatitis B can cause chronic infection and increases the risk of death from cirrhosis and liver cancer.

The increase in rate of hepatitis B and rise in awareness about hepatitis B drive the growth of the market. For instance, according to a report of World Health Organization (WHO) published in June 2022, globally, an estimated 296 million people were living with chronic hepatitis B infection in 2019, with 1.5 million new infections each year. Thus, increase in prevalence of hepatitis B globally boosts the growth of the market.

In addition, factors such as increase in blood donation and rise in blood transfusion rate foster the growth of the market. The blood transfusion is a leading cause of hepatitis B virus transmission. For instance, as per the report of World Health Organization (WHO) published in May 2022, about 118.54 million blood donations are made worldwide. About 40% of these are collected in high-income countries. The World Health Organization (WHO) recommends that all blood donations should be screened for infections prior to use. Screening for HIV, hepatitis B, hepatitis c, and syphilis should be mandatory.

Moreover, increase in R&D activities for development of novel chronic hepatitis B treatment, rise in the U.S. food & drug administration (FDA) approvals and novel product launch in the market by key players boost the market growth. For instance, in June 2022, glaxosmithkline (GSK), a science-led global healthcare company, announced the interim results from the B-Clear phase IIb trial showing that bepirovirsen, an investigational antisense oligonucleotide treatment for hepatitis B, reduced levels of hepatitis B surface antigen (HBsAg) and hepatitis B virus (HBV) DNA after 24 weeks' treatment in people with chronic hepatitis B (CHB). Furthermore, advancements in hepatitis B treatment and rise in diagnosis rate further contribute toward the market growth. However, high cost of chronic hepatitis B drugs is projected to hinder the growth of the market.

The chronic hepatitis B market is segmented on the basis of drug class, gender, distribution channel, and region. By drug class, the market is fragmented into antivirals, and immune modulators. By gender, the market is classified into male, and female. The male segment is further divided into adult and geriatric. The female segment is further divided into adult and geriatric. By distribution channel, the market is categorized into hospital pharmacies, drug stores & retail pharmacies, and online providers. By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The major companies profiled in the report include Biocon Inc, Cipla Limited, Dr. Reddy's Laboratories, Gilead Sciences, Inc., Novartis AG, Reliance Life Sciences, Sun Pharmaceutical Industries Limited, Teva pharmaceuticals, Viatris Inc and Zydus Cadila.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the chronic hepatitis b (chb) market analysis from 2021 to 2031 to identify the prevailing chronic hepatitis b (chb) market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the chronic hepatitis b (chb) market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global chronic hepatitis b (chb) market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Drug Class

Antivirals
Immune Modulators

By Gender

Male
- Age Group
- Adult
- Geriartic
Female
- Age Group
- Adult
- Geriartic

By Distribution Channel

Hospital Pharmacies
Drug Stores and Retail Pharmacies
Online Providers

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest Of Europe
Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest Of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest Of LAMEA
Key Market Players
- GlaxoSmithKline (GSK)
- Gilead Sciences, Inc.
- Merck & Co. Inc.
- Bristol Myers Squibb Co.
- Teva Pharmaceutical Industries Limited
- zydus cadila
- Novartis AG
- F. Hoffman La Roche, Ltd.
- Viatris Inc. (Mylan NV)
- Cipla Ltd

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

3.1.Market definition and scope
3.2.Key findings
- 3.2.1.Top investment pockets
3.3.Porter's five forces analysis
3.4.Top player positioning
3.5.Market dynamics
- 3.5.1.Drivers
- 3.5.2.Restraints
- 3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: CHRONIC HEPATITIS B (CHB) MARKET, BY DRUG CLASS

4.1 Overview
- 4.1.1 Market size and forecast
4.2 Antivirals
- 4.2.1 Key market trends, growth factors and opportunities
- 4.2.2 Market size and forecast, by region
- 4.2.3 Market analysis by country
4.3 Immune Modulators
- 4.3.1 Key market trends, growth factors and opportunities
- 4.3.2 Market size and forecast, by region
- 4.3.3 Market analysis by country

CHAPTER 5: CHRONIC HEPATITIS B (CHB) MARKET, BY GENDER

5.1 Overview
- 5.1.1 Market size and forecast
5.2 Male
- 5.2.1 Key market trends, growth factors and opportunities
- 5.2.2 Market size and forecast, by region
- 5.2.3 Market analysis by country
- 5.2.4 Male Chronic Hepatitis B (CHB) Market by Age Group
  - 5.2.4.1 Adult Market size and forecast, by region
  - 5.2.4.2 Geriartic Market size and forecast, by region
5.3 Female
- 5.3.1 Key market trends, growth factors and opportunities
- 5.3.2 Market size and forecast, by region
- 5.3.3 Market analysis by country
- 5.3.4 Female Chronic Hepatitis B (CHB) Market by Age Group
  - 5.3.4.1 Adult Market size and forecast, by region
  - 5.3.4.2 Geriartic Market size and forecast, by region

CHAPTER 6: CHRONIC HEPATITIS B (CHB) MARKET, BY DISTRIBUTION CHANNEL

6.1 Overview
- 6.1.1 Market size and forecast
6.2 Hospital Pharmacies
- 6.2.1 Key market trends, growth factors and opportunities
- 6.2.2 Market size and forecast, by region
- 6.2.3 Market analysis by country
6.3 Drug Stores and Retail Pharmacies
- 6.3.1 Key market trends, growth factors and opportunities
- 6.3.2 Market size and forecast, by region
- 6.3.3 Market analysis by country
6.4 Online Providers
- 6.4.1 Key market trends, growth factors and opportunities
- 6.4.2 Market size and forecast, by region
- 6.4.3 Market analysis by country

CHAPTER 7: CHRONIC HEPATITIS B (CHB) MARKET, BY REGION

7.1 Overview
- 7.1.1 Market size and forecast
7.2 North America
- 7.2.1 Key trends and opportunities
- 7.2.2 North America Market size and forecast, by Drug Class
- 7.2.3 North America Market size and forecast, by Gender
  - 7.2.3.1 North America Male Chronic Hepatitis B (CHB) Market by Age Group
  - 7.2.3.2 North America Female Chronic Hepatitis B (CHB) Market by Age Group
- 7.2.4 North America Market size and forecast, by Distribution Channel
- 7.2.5 North America Market size and forecast, by country
  - 7.2.5.1 U.S.
  - 7.2.5.1.1 Market size and forecast, by Drug Class
  - 7.2.5.1.2 Market size and forecast, by Gender
  - 7.2.5.1.3 Market size and forecast, by Distribution Channel
  - 7.2.5.2 Canada
  - 7.2.5.2.1 Market size and forecast, by Drug Class
  - 7.2.5.2.2 Market size and forecast, by Gender
  - 7.2.5.2.3 Market size and forecast, by Distribution Channel
  - 7.2.5.3 Mexico
  - 7.2.5.3.1 Market size and forecast, by Drug Class
  - 7.2.5.3.2 Market size and forecast, by Gender
  - 7.2.5.3.3 Market size and forecast, by Distribution Channel
7.3 Europe
- 7.3.1 Key trends and opportunities
- 7.3.2 Europe Market size and forecast, by Drug Class
- 7.3.3 Europe Market size and forecast, by Gender
  - 7.3.3.1 Europe Male Chronic Hepatitis B (CHB) Market by Age Group
  - 7.3.3.2 Europe Female Chronic Hepatitis B (CHB) Market by Age Group
- 7.3.4 Europe Market size and forecast, by Distribution Channel
- 7.3.5 Europe Market size and forecast, by country
  - 7.3.5.1 Germany
  - 7.3.5.1.1 Market size and forecast, by Drug Class
  - 7.3.5.1.2 Market size and forecast, by Gender
  - 7.3.5.1.3 Market size and forecast, by Distribution Channel
  - 7.3.5.2 France
  - 7.3.5.2.1 Market size and forecast, by Drug Class
  - 7.3.5.2.2 Market size and forecast, by Gender
  - 7.3.5.2.3 Market size and forecast, by Distribution Channel
  - 7.3.5.3 UK
  - 7.3.5.3.1 Market size and forecast, by Drug Class
  - 7.3.5.3.2 Market size and forecast, by Gender
  - 7.3.5.3.3 Market size and forecast, by Distribution Channel
  - 7.3.5.4 Italy
  - 7.3.5.4.1 Market size and forecast, by Drug Class
  - 7.3.5.4.2 Market size and forecast, by Gender
  - 7.3.5.4.3 Market size and forecast, by Distribution Channel
  - 7.3.5.5 Spain
  - 7.3.5.5.1 Market size and forecast, by Drug Class
  - 7.3.5.5.2 Market size and forecast, by Gender
  - 7.3.5.5.3 Market size and forecast, by Distribution Channel
  - 7.3.5.6 Rest of Europe
  - 7.3.5.6.1 Market size and forecast, by Drug Class
  - 7.3.5.6.2 Market size and forecast, by Gender
  - 7.3.5.6.3 Market size and forecast, by Distribution Channel
7.4 Asia-Pacific
- 7.4.1 Key trends and opportunities
- 7.4.2 Asia-Pacific Market size and forecast, by Drug Class
- 7.4.3 Asia-Pacific Market size and forecast, by Gender
  - 7.4.3.1 Asia-Pacific Male Chronic Hepatitis B (CHB) Market by Age Group
  - 7.4.3.2 Asia-Pacific Female Chronic Hepatitis B (CHB) Market by Age Group
- 7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel
- 7.4.5 Asia-Pacific Market size and forecast, by country
  - 7.4.5.1 Japan
  - 7.4.5.1.1 Market size and forecast, by Drug Class
  - 7.4.5.1.2 Market size and forecast, by Gender
  - 7.4.5.1.3 Market size and forecast, by Distribution Channel
  - 7.4.5.2 China
  - 7.4.5.2.1 Market size and forecast, by Drug Class
  - 7.4.5.2.2 Market size and forecast, by Gender
  - 7.4.5.2.3 Market size and forecast, by Distribution Channel
  - 7.4.5.3 Australia
  - 7.4.5.3.1 Market size and forecast, by Drug Class
  - 7.4.5.3.2 Market size and forecast, by Gender
  - 7.4.5.3.3 Market size and forecast, by Distribution Channel
  - 7.4.5.4 India
  - 7.4.5.4.1 Market size and forecast, by Drug Class
  - 7.4.5.4.2 Market size and forecast, by Gender
  - 7.4.5.4.3 Market size and forecast, by Distribution Channel
  - 7.4.5.5 South Korea
  - 7.4.5.5.1 Market size and forecast, by Drug Class
  - 7.4.5.5.2 Market size and forecast, by Gender
  - 7.4.5.5.3 Market size and forecast, by Distribution Channel
  - 7.4.5.6 Rest of Asia-Pacific
  - 7.4.5.6.1 Market size and forecast, by Drug Class
  - 7.4.5.6.2 Market size and forecast, by Gender
  - 7.4.5.6.3 Market size and forecast, by Distribution Channel
7.5 LAMEA
- 7.5.1 Key trends and opportunities
- 7.5.2 LAMEA Market size and forecast, by Drug Class
- 7.5.3 LAMEA Market size and forecast, by Gender
  - 7.5.3.1 LAMEA Male Chronic Hepatitis B (CHB) Market by Age Group
  - 7.5.3.2 LAMEA Female Chronic Hepatitis B (CHB) Market by Age Group
- 7.5.4 LAMEA Market size and forecast, by Distribution Channel
- 7.5.5 LAMEA Market size and forecast, by country
  - 7.5.5.1 Brazil
  - 7.5.5.1.1 Market size and forecast, by Drug Class
  - 7.5.5.1.2 Market size and forecast, by Gender
  - 7.5.5.1.3 Market size and forecast, by Distribution Channel
  - 7.5.5.2 Saudi Arabia
  - 7.5.5.2.1 Market size and forecast, by Drug Class
  - 7.5.5.2.2 Market size and forecast, by Gender
  - 7.5.5.2.3 Market size and forecast, by Distribution Channel
  - 7.5.5.3 South Africa
  - 7.5.5.3.1 Market size and forecast, by Drug Class
  - 7.5.5.3.2 Market size and forecast, by Gender
  - 7.5.5.3.3 Market size and forecast, by Distribution Channel
  - 7.5.5.4 Rest of LAMEA
  - 7.5.5.4.1 Market size and forecast, by Drug Class
  - 7.5.5.4.2 Market size and forecast, by Gender
  - 7.5.5.4.3 Market size and forecast, by Distribution Channel

CHAPTER 8: COMPANY LANDSCAPE

8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments

CHAPTER 9: COMPANY PROFILES

9.1 GlaxoSmithKline (GSK)
- 9.1.1 Company overview
- 9.1.2 Company snapshot
- 9.1.3 Operating business segments
- 9.1.4 Product portfolio
- 9.1.5 Business performance
- 9.1.6 Key strategic moves and developments
9.2 Gilead Sciences, Inc.
- 9.2.1 Company overview
- 9.2.2 Company snapshot
- 9.2.3 Operating business segments
- 9.2.4 Product portfolio
- 9.2.5 Business performance
- 9.2.6 Key strategic moves and developments
9.3 Merck & Co. Inc.
- 9.3.1 Company overview
- 9.3.2 Company snapshot
- 9.3.3 Operating business segments
- 9.3.4 Product portfolio
- 9.3.5 Business performance
- 9.3.6 Key strategic moves and developments
9.4 Bristol Myers Squibb Co.
- 9.4.1 Company overview
- 9.4.2 Company snapshot
- 9.4.3 Operating business segments
- 9.4.4 Product portfolio
- 9.4.5 Business performance
- 9.4.6 Key strategic moves and developments
9.5 Teva Pharmaceutical Industries Limited
- 9.5.1 Company overview
- 9.5.2 Company snapshot
- 9.5.3 Operating business segments
- 9.5.4 Product portfolio
- 9.5.5 Business performance
- 9.5.6 Key strategic moves and developments
9.6 zydus cadila
- 9.6.1 Company overview
- 9.6.2 Company snapshot
- 9.6.3 Operating business segments
- 9.6.4 Product portfolio
- 9.6.5 Business performance
- 9.6.6 Key strategic moves and developments
9.7 Novartis AG
- 9.7.1 Company overview
- 9.7.2 Company snapshot
- 9.7.3 Operating business segments
- 9.7.4 Product portfolio
- 9.7.5 Business performance
- 9.7.6 Key strategic moves and developments
9.8 F. Hoffman La Roche, Ltd.
- 9.8.1 Company overview
- 9.8.2 Company snapshot
- 9.8.3 Operating business segments
- 9.8.4 Product portfolio
- 9.8.5 Business performance
- 9.8.6 Key strategic moves and developments
9.9 Viatris Inc. (Mylan NV)
- 9.9.1 Company overview
- 9.9.2 Company snapshot
- 9.9.3 Operating business segments
- 9.9.4 Product portfolio
- 9.9.5 Business performance
- 9.9.6 Key strategic moves and developments
9.10 Cipla Ltd
- 9.10.1 Company overview
- 9.10.2 Company snapshot
- 9.10.3 Operating business segments
- 9.10.4 Product portfolio
- 9.10.5 Business performance
- 9.10.6 Key strategic moves and developments

B型慢性肝炎市場：薬物クラス別、性別、流通チャネル別：世界の機会分析および産業予測、2021-2031年

Chronic Hepatitis B Market By Drug Class, By Gender, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2021-2031

目次

第1章イントロダクション

第2章エグゼクティブサマリー

第3章市場の概要

第4章慢性肝炎（CHB）市場：薬効分類別

第5章慢性肝炎B（CHB）市場：男女別

第6章 B型慢性肝炎（CHB）市場：流通チャネル別

第7章慢性肝炎B（CHB）市場：地域別

第8章企業情勢

第9章企業プロファイル

LIST OF TABLES

LIST OF FIGURES

Key Market Segments

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

CHAPTER 2:EXECUTIVE SUMMARY

CHAPTER 3:MARKET OVERVIEW

CHAPTER 4: CHRONIC HEPATITIS B (CHB) MARKET, BY DRUG CLASS

CHAPTER 5: CHRONIC HEPATITIS B (CHB) MARKET, BY GENDER

CHAPTER 6: CHRONIC HEPATITIS B (CHB) MARKET, BY DISTRIBUTION CHANNEL

CHAPTER 7: CHRONIC HEPATITIS B (CHB) MARKET, BY REGION

CHAPTER 8: COMPANY LANDSCAPE

CHAPTER 9: COMPANY PROFILES

B型慢性肝炎市場：薬物クラス別、性別、流通チャネル別：世界の機会分析および産業予測、2021-2031年

Chronic Hepatitis B Market By Drug Class, By Gender, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2021-2031

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場の概要

第4章 慢性肝炎（CHB）市場：薬効分類別

第5章 慢性肝炎B（CHB）市場： 男女別

第6章 B型慢性肝炎（CHB）市場： 流通チャネル別

第7章 慢性肝炎B（CHB）市場： 地域別

第8章 企業情勢

第9章 企業プロファイル

LIST OF TABLES

LIST OF FIGURES

Key Market Segments

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

CHAPTER 2:EXECUTIVE SUMMARY

CHAPTER 3:MARKET OVERVIEW

CHAPTER 4: CHRONIC HEPATITIS B (CHB) MARKET, BY DRUG CLASS

CHAPTER 5: CHRONIC HEPATITIS B (CHB) MARKET, BY GENDER

CHAPTER 6: CHRONIC HEPATITIS B (CHB) MARKET, BY DISTRIBUTION CHANNEL

CHAPTER 7: CHRONIC HEPATITIS B (CHB) MARKET, BY REGION

CHAPTER 8: COMPANY LANDSCAPE

CHAPTER 9: COMPANY PROFILES

第1章イントロダクション

第2章エグゼクティブサマリー

第3章市場の概要

第4章慢性肝炎（CHB）市場：薬効分類別

第5章慢性肝炎B（CHB）市場：男女別

第6章 B型慢性肝炎（CHB）市場：流通チャネル別

第7章慢性肝炎B（CHB）市場：地域別

第8章企業情勢

第9章企業プロファイル